ISA Pharmaceuticals
Miranda Molenaar has been working in the life sciences industry since 1995. Miranda began their career as a PhD student at the Hubrecht Laboratory/Netherlands Institute for Developmental Biology. In 2000, they moved to Crucell as a Scientist. In 2005, they joined Genmab as an Associate Director of New Products and Program Manager. In 2012, they joined ISA Pharmaceuticals as Intellectual Property & Business Strategy. In 2018, they moved to the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital as a Business Development Manager. In 2019, they joined Oncode Institute as a Business Development Manager. During their time at M.m Biotech Intelligence from 2009 to 2012, they provided business intelligence, assessed the merit and strategic fit of biologic targeted therapy, and published several key papers.
Miranda Molenaar obtained their PhD in Developmental Biology and Cancer Biology from Utrecht University between 1995 and 2000.
This person is not in any offices
ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology.